Evommune (EVMN) Corporate presentation summary

Addressing chronic inflammation and unmet medical needs

• Chronic inflammation contributes to 3 out of 5 deaths globally and imposes an annual direct cost of at least $90B on healthcare systems.

• Current therapies for chronic inflammatory diseases have critical limitations in efficacy and safety for most patients.

• The company is advancing next-generation therapies with distinct mechanisms and a portfolio approach targeting immune-mediated diseases.

Pipeline overview and clinical programs

• EVO756 is an oral MRGPRX2 antagonist in Phase 2b for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), with a migraine trial planned for mid-2026.

• EVO301 is a long-acting IL-18 binding protein fusion protein in Phase 2b for AD, with positive Phase 2a proof-of-concept data.

• Multiple preclinical programs are advancing toward clinical proof-of-concept.

EVO756 clinical data and potential

• EVO756 demonstrated robust clinical activity and was well-tolerated in Phase 1 and Phase 2 trials for urticaria, with 30% complete response at 4 weeks.

• Pharmacokinetic modeling supports both QD and BID dosing regimens, with strong target engagement and dose-proportional exposure.

• Phase 2b trials in CSU and AD are expected to deliver topline data in Q2 and Q3 2026, respectively.

• EVO756's dual mechanism targets both mast cells and sensory neurons, offering potential benefits across multiple inflammatory and neuroinflammatory diseases.